Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Cirrhotic Patients with Portal Vein Thrombosis
NCT03631147Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2018
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in portal vein thrombosis (PVT), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Changes of portal vein thrombosis at 8 weeks. Status: unknown.
02
Drugs
rifaximin
03
Conditions
portal vein thrombosis (PVT)
Beyond the preview
Go deeper on NCT03631147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03631147.